Recent advances of SHP2 inhibitors in cancer therapy: current development and clinical application
X Yuan, H Bu, J Zhou, CY Yang… - Journal of medicinal …, 2020 - ACS Publications
SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase-2) is a non-
receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally …
receptor protein tyrosine phosphatase that removes tyrosine phosphorylation. Functionally …
[HTML][HTML] Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies
Src homology containing protein tyrosine phosphatase 2 (SHP2) represents a noteworthy
target for various diseases, serving as a well-known oncogenic phosphatase in cancers. As …
target for various diseases, serving as a well-known oncogenic phosphatase in cancers. As …
[HTML][HTML] Strategies to overcome drug resistance using SHP2 inhibitors
M Liu, S Gao, RM Elhassan, X Hou, H Fang - Acta Pharmaceutica Sinica B, 2021 - Elsevier
Encoded by PTPN11, the SHP2 (Src homology-2 domain-containing protein tyrosine
phosphatase-2) is widely recognized as a carcinogenic phosphatase. As a promising anti …
phosphatase-2) is widely recognized as a carcinogenic phosphatase. As a promising anti …
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
The nonreceptor protein tyrosine phosphatase SHP2 (encoded by PTPN11) integrates
growth and differentiation signals from receptor tyrosine kinases (RTKs) into the …
growth and differentiation signals from receptor tyrosine kinases (RTKs) into the …
A comprehensive review of SHP2 and its role in cancer
MD Asmamaw, XJ Shi, LR Zhang, HM Liu - Cellular Oncology, 2022 - Springer
Src homology 2-containing protein tyrosine phosphatase 2 (SHP2) is a non-receptor protein
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …
tyrosine phosphatase ubiquitously expressed mainly in the cytoplasm of several tissues …
Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor
J Garcia Fortanet, CHT Chen, YNP Chen… - Journal of medicinal …, 2016 - ACS Publications
SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also …
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also …
Allosteric inhibitors of SHP2 with therapeutic potential for cancer treatment
SHP2, a cytoplasmic protein-tyrosine phosphatase encoded by the PTPN11 gene, is
involved in multiple cell signaling processes including Ras/MAPK and Hippo/YAP pathways …
involved in multiple cell signaling processes including Ras/MAPK and Hippo/YAP pathways …
Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials
Phosphorylation is a reversible post-translational modification regulated by phosphorylase
and dephosphorylase to mediate important cellular events. Src homology-2-containing …
and dephosphorylase to mediate important cellular events. Src homology-2-containing …
Functions of Shp2 in cancer
J Zhang, F Zhang, R Niu - Journal of cellular and molecular …, 2015 - Wiley Online Library
Diagnostics and therapies have shown evident advances. Tumour surgery, chemotherapy
and radiotherapy are the main techniques in treat cancers. Targeted therapy and drug …
and radiotherapy are the main techniques in treat cancers. Targeted therapy and drug …
Identification of TNO155, an allosteric SHP2 inhibitor for the treatment of cancer
MJ LaMarche, M Acker, A Argintaru… - Journal of medicinal …, 2020 - ACS Publications
SHP2 is a nonreceptor protein tyrosine phosphatase encoded by the PTPN11 gene and is
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays …
involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also plays …
相关搜索
- shp2 inhibitors cancer therapy
- shp2 inhibitors clinical application
- allosteric shp2 inhibitor
- shp2 inhibitor treatment of cancer
- shp2 inhibitors immune microenvironment
- shp2 inhibitors drug resistance
- therapeutic potential allosteric inhibitors
- cancer therapy clinical application
- cancer treatment allosteric inhibitors
- therapeutic potential shp2 phosphatase